Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 163

1.

Diagnostic utility of faecal biomarkers in patients with irritable bowel syndrome.

Däbritz J, Musci J, Foell D.

World J Gastroenterol. 2014 Jan 14;20(2):363-75. doi: 10.3748/wjg.v20.i2.363. Review.

2.

Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome.

Kaiser T, Langhorst J, Wittkowski H, Becker K, Friedrich AW, Rueffer A, Dobos GJ, Roth J, Foell D.

Gut. 2007 Dec;56(12):1706-13. Epub 2007 Aug 3.

3.

Faecal markers of gastrointestinal inflammation.

Sherwood RA.

J Clin Pathol. 2012 Nov;65(11):981-5. doi: 10.1136/jclinpath-2012-200901. Epub 2012 Jul 19. Review.

PMID:
22813730
4.

Faecal lactoferrin--a novel test to differentiate between the irritable and inflamed bowel?

Sidhu R, Wilson P, Wright A, Yau CW, D'Cruz FA, Foye L, Morley S, Lobo AJ, McAlindon ME, Sanders DS.

Aliment Pharmacol Ther. 2010 Jun;31(12):1365-70. doi: 10.1111/j.1365-2036.2010.04306.x. Epub 2010 Mar 20.

5.

Faecal calprotectin testing for differentiating amongst inflammatory and non-inflammatory bowel diseases: systematic review and economic evaluation.

Waugh N, Cummins E, Royle P, Kandala NB, Shyangdan D, Arasaradnam R, Clar C, Johnston R.

Health Technol Assess. 2013 Nov;17(55):xv-xix, 1-211. doi: 10.3310/hta17550. Review.

6.

Faecal calprotectin as a novel biomarker for differentiating between inflammatory bowel disease and irritable bowel syndrome.

Chang MH, Chou JW, Chen SM, Tsai MC, Sun YS, Lin CC, Lin CP.

Mol Med Rep. 2014 Jul;10(1):522-6. doi: 10.3892/mmr.2014.2180. Epub 2014 Apr 24.

PMID:
24788223
7.

Fecal leukocyte proteins in inflammatory bowel disease and irritable bowel syndrome.

Silberer H, Küppers B, Mickisch O, Baniewicz W, Drescher M, Traber L, Kempf A, Schmidt-Gayk H.

Clin Lab. 2005;51(3-4):117-26.

PMID:
15819166
8.

Diagnostic performance of rapid tests for detection of fecal calprotectin and lactoferrin and their ability to discriminate inflammatory from irritable bowel syndrome.

Otten CM, Kok L, Witteman BJ, Baumgarten R, Kampman E, Moons KG, de Wit NJ.

Clin Chem Lab Med. 2008;46(9):1275-80. doi: 10.1515/CCLM.2008.246. Erratum in: Clin Chem Lab Med. 2008;46(12):1798.

PMID:
18597588
9.
10.

Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices.

Langhorst J, Elsenbruch S, Koelzer J, Rueffer A, Michalsen A, Dobos GJ.

Am J Gastroenterol. 2008 Jan;103(1):162-9. Epub 2007 Oct 4.

PMID:
17916108
11.

Fecal markers: calprotectin and lactoferrin.

Abraham BP, Kane S.

Gastroenterol Clin North Am. 2012 Jun;41(2):483-95. doi: 10.1016/j.gtc.2012.01.007. Epub 2012 Feb 16. Review.

PMID:
22500530
12.

A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS.

Menees SB, Powell C, Kurlander J, Goel A, Chey WD.

Am J Gastroenterol. 2015 Mar;110(3):444-54. doi: 10.1038/ajg.2015.6. Epub 2015 Mar 3. Review.

PMID:
25732419
13.

Fecal calprotectin is an effective diagnostic tool that differentiates inflammatory from functional intestinal disorders.

Caviglia GP, Pantaleoni S, Touscoz GA, Adriani A, Rosso C, Smedile A, Pellicano R, Astegiano M, Bresso F.

Scand J Gastroenterol. 2014 Dec;49(12):1419-24. doi: 10.3109/00365521.2014.934913. Epub 2014 Nov 5.

14.

Semiquantitative fecal calprotectin test in postinfectious and non-postinfectious irritable bowel syndrome: cross-sectional study.

David LE, Surdea-Blaga T, Dumitrascu DL.

Sao Paulo Med J. 2015 Jul-Aug;133(4):343-9. doi: 10.1590/1516-3180.2014.8000815. Epub 2014 Dec 19.

15.

Fecal M2-pyruvate kinase (M2-PK): a novel marker of intestinal inflammation.

Chung-Faye G, Hayee B, Maestranzi S, Donaldson N, Forgacs I, Sherwood R.

Inflamm Bowel Dis. 2007 Nov;13(11):1374-8.

PMID:
17577247
16.

Comparison of two immunoassays for measurement of faecal calprotectin in detection of inflammatory bowel disease: (pre)-analytical and diagnostic performance characteristics.

Oyaert M, Trouvé C, Baert F, De Smet D, Langlois M, Vanpoucke H.

Clin Chem Lab Med. 2014 Mar;52(3):391-7. doi: 10.1515/cclm-2013-0699.

PMID:
24114912
17.

Accuracy of four fecal assays in the diagnosis of colitis.

Schoepfer AM, Trummler M, Seeholzer P, Criblez DH, Seibold F.

Dis Colon Rectum. 2007 Oct;50(10):1697-706.

PMID:
17762964
18.

Fecal lactoferrin in discriminating inflammatory bowel disease from irritable bowel syndrome: a diagnostic meta-analysis.

Zhou XL, Xu W, Tang XX, Luo LS, Tu JF, Zhang CJ, Xu X, Wu QD, Pan WS.

BMC Gastroenterol. 2014 Jul 7;14:121. doi: 10.1186/1471-230X-14-121. Review.

19.

Irritable bowel syndrome and active inflammatory bowel disease diagnosed by faecal gas analysis.

Aggio RB, White P, Jayasena H, de Lacy Costello B, Ratcliffe NM, Probert CS.

Aliment Pharmacol Ther. 2017 Jan;45(1):82-90. doi: 10.1111/apt.13822. Epub 2016 Nov 10.

PMID:
27862117
20.

Non-invasive investigation of inflammatory bowel disease.

Tibble JA, Bjarnason I.

World J Gastroenterol. 2001 Aug;7(4):460-5. Review.

Supplemental Content

Support Center